U.S. Launch of a Ex-U.S. Oncology Agent
Prepared a small biotechnology company for the U.S. launch of a new oral oncology agent by supporting the commercial team’s focus on challenges associated with U.S. commercial entrance of an ex-U.S. company, providing payer management strategies under the medical vs the pharmacy benefit, and using pathways and other UM tools – prior authorization, tiering, and current and future impact of pricing strategy on access.